The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Gene therapies for BCG-unresponsive bladder cancer have high response rates.

2.

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

3.

improvements in the treatment of prostate cancer resistant to chemotherapy.

4.

AI could help improve early detection of interval breast cancers

5.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot